52241-26-6Relevant articles and documents
Maloplatin-B, a Cisplatin-Based BODIPY-Tagged Mito-Specific chemo-PDT Agent Active in Red Light
Ramu, Vanitha,Kundu, Paramita,Kondaiah, Paturu,Chakravarty, Akhil R.
supporting information, p. 6410 - 6420 (2021/05/06)
Maloplatin-B, a cisplatin-based complex, namely [Pt(A-BOD)(NH3)2](NO3) (Pt-A-BOD) with a pendant boron-dipyrromethene (BODIPY) moiety, where HA-BOD is a methyl malonyl chloride derived monostyryl BODIPY ligand, was designed and developed as near-IR light (600-720 nm) organelle-targeting photodynamic therapy agent. The complex [Pt(acac)(NH3)2](NO3) (Pt-Ac) was used as a control. Pt-A-BOD displayed an absorption band at 616 nm (? = 2.9 × 104 M-1 cm-1) in 10% dimethyl sulfoxide/Dulbecco's Modified Eagle's Medium (DMSO/DMEM, pH 7.2). This complex displayed a broad emission band within 650-850 nm with a λem value of 720 nm in 10% DMSO-DMEM (pH 7.2) upon excitation (λex) at 615 nm with a large Stokes shift. The fluorescence quantum yield (φF) value for Pt-A-BOD is 0.032 and for the ligand HA-BOD is 0.24. The BODIPY complex and ligand showed the formation of singlet oxygen as the ROS (reactive oxygen species) on irradiation with near-IR red light of 660 nm, as evidenced from a 1,3-diphenylisobenzofuran (DPBF) assay. The complex displayed remarkable apoptotic NIR light-induced PDT activity with half-maximum inhibitory concentration values (IC50) of 1.6-2.4 μM in A549 lung and HeLa cervical cancer cells, while it was less active in the dark. The cellular ROS generation by the complex in red light was ascertained by a DCFDA (2′,7′-dichlorofluorescein diacetate) assay. Cellular imaging showed its localization primarily in the mitochondria of A549 cancer cells. The JC1 and Annexin-V FITC/PI assays carried out for A549 cancer cells treated with the BODIPY complex showed the alteration of mitochondrial membrane potential and apoptotic cell death on near-IR red light (600-720 nm) irradiation, respectively.
Kinetic and Thermodynamic Investigation of Human Serum Albumin Interaction with Anticancer Glycine Derivative of Platinum Complex by Using Spectroscopic Methods and Molecular Docking
Shiekhzadeh, Afrooz,Sohrabi, Nasrin,Moghadam, Mahboube Eslami,Oftadeh, Mohsen
, p. 506 - 528 (2019/08/12)
In this paper, a new anticancer Pt (II) complex, cis-[Pt (NH3)2(tertpentylgly)]NO3, was synthesized with glycine-derivative ligand and characterized. Cytotoxicity of this water-soluble Pt complex was studied against human cancer breast cell line of MCF-7. The interaction of human serum albumin (HSA) with Pt complex was studied by using UV-Vis, fluorescence spectroscopy methods, and molecular docking at 27 and 37?°C in the physiological situation (I = 10?mM, pH = 7.4). The negative ΔHb0 and positive ΔSb0 indicated that electrostatic force may be a major mode in the binding between Pt complex and HSA. Binding constant values were obtained through UV-Vis and fluorescence spectroscopy that reveal strong interaction. The negative Gibbs free energy that was obtained by using the UV-Vis method offers spontaneous interaction. Fluorescence quenching the intensity of HSA by adding Pt complex confirms the static mode of interaction is effective for this binding process. Hill coefficients, nH, Hill constant, kH, complex aggregation number around HSA, , number of binding sites, g, HSA melting temperature, Tm, and Stern-Volmer constant, kSV, were also obtained. The kinetics of the interaction was studied, which showed a second-order kinetic. The results of molecular docking demonstrate the position of binding of Pt complex on HSA is the site I in the subdomain IIA.
PLATINUM COMPLEXES AND METHODS OF USE THEREOF
-
Page/Page column 23, (2018/03/28)
Disclosed herein are platinum(II) complexes that can include complexes of the formula, or pharmaceutically acceptable salts thereof, wherein: R1 and R2 are independently selected from the group consisting of an amine, an optionally substituted amine, and an optionally substituted heterocyclic amine; or the pair of R1 and R2 are joined together to form a bidentate ligand containing nitrogen atoms; R3 is selected from the group consisting of H, alkyl optionally substituted, aryl optionally substituted, thienyl optionally substituted, and polyethylene glycol; R4, R5, R6, and R7 are independently selected from the group consisting of H, halide, -OR, alkyl optionally substituted and polyethylene glycol, or each pair of R4 and R5, R5 and R6, R6 and R7 is joined together to form Y is selected from a group consisting of a sulfur atom, oxygen atom, and NR (wherein R is selected from the group consisting of H and alkyl optionally substituted); Z is selected from a group consisting of a carbon atom and a nitrogen atom; and X is selected from a group consisting of fluoride, chloride, bromide, iodide, trifluoromethanesulfonate, acetate, nitrate, perchlorate, hexafluorophosphate, sulfate and phosphate. Also disclosed are methods for using the platinum (II) complexes in the treatment of cancer and in the visualization inside cells.
